MGTX Stock Overview
A clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
MeiraGTx Holdings plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.29 |
| 52 Week High | US$7.37 |
| 52 Week Low | US$3.85 |
| Beta | 1.26 |
| 1 Month Change | 3.28% |
| 3 Month Change | 8.26% |
| 1 Year Change | 6.43% |
| 3 Year Change | -55.74% |
| 5 Year Change | -68.20% |
| Change since IPO | -58.07% |
Recent News & Updates
MeiraGTx: 2 Possible Near-Term BLA Filings Could Ignite Shareholder Value
Jan 22Analysts Have Lowered Expectations For MeiraGTx Holdings plc (NASDAQ:MGTX) After Its Latest Results
Nov 15
Recent updates
MeiraGTx: 2 Possible Near-Term BLA Filings Could Ignite Shareholder Value
Jan 22Analysts Have Lowered Expectations For MeiraGTx Holdings plc (NASDAQ:MGTX) After Its Latest Results
Nov 15MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings
Oct 15MeiraGTx: A Very Attractive Longer-Term Play, With Potential Near-Term Catalysts
Jul 15MeiraGTx Holdings (NASDAQ:MGTX) Has Debt But No Earnings; Should You Worry?
Jun 19MeiraGTx: Bota-Vec Program Advancing With Milestones Being Met
Feb 15Does MeiraGTx Holdings (NASDAQ:MGTX) Have A Healthy Balance Sheet?
Sep 08Calculating The Intrinsic Value Of MeiraGTx Holdings plc (NASDAQ:MGTX)
Apr 11MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are Reducing Their Forecasts For This Year
Mar 16MeiraGTx Holdings plc (NASDAQ:MGTX) Analysts Are More Bearish Than They Used To Be
Nov 16MeiraGTx GAAP EPS of -$0.76, revenue of $10.76M
Aug 11MeiraGTx inks $100M debt agreement backed by manufacturing facilities
Aug 03MeiraGTx Holdings (NASDAQ:MGTX) Is In A Good Position To Deliver On Growth Plans
Apr 29Shareholder Returns
| MGTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.3% | 1.7% | -0.9% |
| 1Y | 6.4% | -2.2% | 22.6% |
Return vs Industry: MGTX exceeded the US Biotechs industry which returned -3.8% over the past year.
Return vs Market: MGTX underperformed the US Market which returned 24.3% over the past year.
Price Volatility
| MGTX volatility | |
|---|---|
| MGTX Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: MGTX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MGTX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 389 | Alexandria Forbes | meiragtx.com |
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson’s program that has completed a Phase II trial.
MeiraGTx Holdings plc Fundamentals Summary
| MGTX fundamental statistics | |
|---|---|
| Market cap | US$502.53m |
| Earnings (TTM) | -US$88.18m |
| Revenue (TTM) | US$13.93m |
35.3x
P/S Ratio-5.6x
P/E RatioIs MGTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MGTX income statement (TTM) | |
|---|---|
| Revenue | US$13.93m |
| Cost of Revenue | US$11.99m |
| Gross Profit | US$1.94m |
| Other Expenses | US$90.12m |
| Earnings | -US$88.18m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.13 |
| Gross Margin | 13.96% |
| Net Profit Margin | -633.05% |
| Debt/Equity Ratio | 76.2% |
How did MGTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 14:17 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
MeiraGTx Holdings plc is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Alec Stranahan | BofA Global Research |
| Gbolahan Amusa Benz | Chardan Capital Markets, LLC |